ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 30 of 71

31 Table 4. Endocrine Toxicities Additional considerations: • Thyroiditis is self-limited and the initial hyperthyroidism generally resolves in weeks with supportive care; most often to primary hypothyroidism or occasionally to normal. Persistent or symptomatic hypothyroidism developing after hyperthyroidism should be treated as above (see section 4.1). • Graves' disease has not been reported with ICPi specifically, but sporadic cases could occur. GD is generally persistent and is treated with anti-thyroid medical therapy, radioactive iodine, or surgery. Endocrine consultation is recommended if suspected. • Physical exam findings of ophthalmopathy or thyroid bruit are diagnostic of Graves' disease and should prompt early endocrine referral. 4.2 Adrenal — Primary adrenal insufficiency (AI) Workup/Evaluation: • Evaluate AM levels of ACTH (if >2× ULN) and cortisol level (if <3 ug/dL). • Basic Metabolic Panel (Na, K, CO 2 , Glucose). • Renin and aldosterone. • Consider standard dose ACTH stimulation test for indeterminate results (AM cortisol >3 ug/dL and <15 ug/dL). • Evaluate for precipitating cause of crisis such as infection. • Adrenal CT for metastasis or hemorrhage (most common causes of primary AI). Grading Management All Grades • Referral to endocrinolog y. • Education on steroid stress dosing, emergency injections, and a medical alert bracelet/necklace, accessory, or system. G1: Asymptomatic or mild symptoms • Consider holding ICPi until patient is stabilized on replacement hormone. • Endocrine consultation. • Initiate replacement therapy with hydrocortisone (15–20 mg in divided doses — see additional considerations). • Titrate hydrocortisone to maximum of 30 mg daily total dose for residual symptoms of AI. • Reduce maintenance dosing for symptoms of iatrogenic Cushing's syndrome (e.g., bruising, thin skin, edema, weight gain, hypertension, hyperglycemia). • Most primary AI will also require fludrocortisone (starting dose 0.5–0.1 mg/day). Adjust based on volume status, sodium level, and renin response (target upper half of the reference range). (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy